Apyx Medical Posts Encouraging Data From Renuvion Device In Sagging Skin

Apyx Medical Corp APYX announced results from Phase 2 of its Investigational Device Exemption (IDE) study of the Renuvion device to improve the appearance of lax skin in the neck and submental region.
The 65-subject study showed that the primary effectiveness endpoint of the study was met, with 82.5% of subjects demonstrating improvement in the appearance of lax skin at six months post-procedure.
Related: Why Apyx Medical Shares Are Trading Higher Today?
96.9% of subjects experienced no to moderate pain during the first seven days following the procedure.
Additional effectiveness endpoints in the study also demonstrated success, with 85.5% of subjects rating themselves as improved and 87.1% of subjects rated improved by the study investigators at the 6-month follow-up visit.
No serious adverse events were reported in the study related to the Renuvion device or the study procedure.
Price Action: APYX shares closed 5.16% higher at $6.93 on Friday.

Momentum91.29

Growth8.81

QualityNot Available

Value55.74

Short

Medium

Long